ProSciento Announces Collaboration with Leading NAFLD/NASH Expert Dr. Rohit Loomba

ProSciento Announces Collaboration with Leading NAFLD/NASH Expert Dr. Rohit Loomba

SAN DIEGO, October 28, 2015 –  ProSciento Inc., a clinical research organization (CRO) focused on diabetes, obesity and NALFD/NASH, today announced a collaboration with Rohit Loomba, M.D., a leading clinical and academic researcher in NAFLD and NASH.

Dr. Loomba’s research focuses on all aspects of NAFLD, including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. His research at UC San Diego has contributed to a number of important milestones, including the establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH; the first prospective study of MRE in patients with biopsy-proven NAFLD; and the first trial in NASH with comprehensive MRI and 2D and 3D MRE assessment paired with liver biopsies in NASH. His research is widely published in peer reviewed journals. He is Director of UC San Diego’s NAFLD Research Center and is the founder and principal investigator of the San Diego Integrated NAFLD Research Consortium (SINC).

“Dr. Loomba is recognized internationally as a leading expert in NAFLD and NASH research.  His team at UCSD has helped pioneer a number of imaging modalities and noninvasive biomarker discoveries, often referred to as ‘virtual biopsies’ for NAFLD/NASH diagnosis, prognosis and disease progression monitoring,” said Dr. Marcus Hompesch, ProSciento’s President and CEO. “This consulting agreement between Dr. Loomba and ProSciento represents the bridging of groundbreaking independent academic science with ProSciento’s expertise and experience in designing and executing complex clinical research and development planning for the biopharmaceutical industry.”

“There’s a tremendous need to find clinical solutions for NAFLD and NASH. Given the comorbidities that exist, ProSciento’s previous work in diabetes, obesity and metabolic disease have allowed its team to develop the clinical research and development expertise to respond to the growing unmet medical need for diagnostics, treatments and monitoring tools,” said Dr. Loomba.

About non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

Non-alcoholic fatty liver disease (NAFLD) is a condition indicated by excess fat deposition in the liver and is a comorbidity of metabolic syndrome, obesity and diabetes. NAFLD is rapidly becoming the most common liver disease globally with population-based estimates ranging from 20 to 30%.1, 2 Among patients with type 2 diabetes, the reported prevalence of NAFLD is 65%.3 In patients with severe obesity, the prevalence of NAFLD can exceed 90%.1, 2

Approximately 10–22% of patients with NAFLD have the progressive subtype non-alcoholic steatohepatitis (NASH), which can result in cirrhosis, hepatocellular carcinoma, and liver failure, often necessitating liver transplantation. 4

About ProSciento, Inc.

ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.

For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
abby.devine@prosciento.com

For business development inquires:
bd@prosciento.com

For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com

 

  1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 2012 Jun;55(6):2005-23.
  2. Ahmed M. Non-alcoholic fatty liver disease in 2015. World Journal of Hepatology. 2015;7:1450-9.
  3. Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015 Sep 15. doi: 10.1111/apt.13405.
  4. Bazick J, Donithan M, Neuschwander-Tetri B, Kleiner D, Brunt E, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015 Apr;10.2337/dc14-1239.